Back to Search
ERMINIA MASSARELLI, MD
MD
Medical Oncology Physician
NPI: 1982855326IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
142539(CA)
Education
OTHER
Class of 1997
Research & Publications (15)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
PMID 17504988·Clin Cancer Res·2007
8-other
Use of novel second-line targeted therapies in non-small cell lung cancer.
PMID 16472704·Semin Oncol·2006
6-review
Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis.
PMID 15666322·Cancer·2005
8-other
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
PMID 12499095·Lung Cancer·2003
8-other
New targets for the treatment of advanced non-small cell lung cancer.
PMID 12703232·Cancer Chemother Biol Response Modif·2002
6-review
Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.
PMID 19138956·Cancer Prev Res (Phila)·2008
8-other
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
PMID 16357156·Cancer Res·2005
7-preclinical
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
PMID 16000569·Clin Cancer Res·2005
1-meta
Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
PMID 15386339·Cancer·2004
6-review
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
PMID 15013588·Lung Cancer·2004
3-trial
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
PMID 14734462·Clin Cancer Res·2004
4-observational
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
PMID 12381900·Oncology·2002
3-trial
Comparative fine structural distribution of endopeptidase 24.15 (EC3.4.24.15) and 24.16 (EC3.4.24.16) in rat brain.
PMID 11559896·J Comp Neurol·2001
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1500 DUARTE RD
DUARTE, CA 91010 - Phone
- (626) 775-3514
Quick Facts
- NPI
- 1982855326
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 15
Are you this provider?
Claim Your Profile